Clinical Trials Directory

Trials / Completed

CompletedNCT01285596

A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex

An Open-label, Randomized, 2-way Crossover Study to Evaluate the Pharmacokinetics of Mirabegron and Its Metabolites in Healthy Young and Elderly Male and Female Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
75 (actual)
Sponsor
Astellas Pharma Inc · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Young and elderly, male and female subjects are each given 2 different doses of mirabegron for 7 days each. Levels of mirabegron in the blood are assessed.

Conditions

Interventions

TypeNameDescription
DRUGMirabegronoral

Timeline

Start date
2009-03-01
Primary completion
2009-11-01
Completion
2009-11-01
First posted
2011-01-28
Last updated
2013-07-03

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01285596. Inclusion in this directory is not an endorsement.